Stephen Munk

iMetabolic Biopharma Corporation (iMBP) is an exciting early stage platform biopharma company that is developing First In Class therapeutics for the treatment of a number of diseases with high unmet medical need. Through the application of its proprietary iPlatform technology, iMBP has established itself as a Leader in TechBio, a nouveau field of drug discovery and development driven by technology innovation. Having already established a pipeline of five early stage therapeutic assets, with additional molecules already in design phase, iMBP is at the precipice in its next leg of evolution. Based in Tempe, AZ; iMBP is growing its operations to support the development of both its platform technology and therapeutic pipeline. iMBP is now strategically poised to become a disruptive force in the biopharma industry and is poised to move forward ground breaking science to help improve patient care. https://l.instagram.com/?u=https%3A%2F%2Flinktr.ee%2Fdr_urban_a_kiernan&e=AT1Hx7OAnm1Esgp1qPUsti_FJonAgqb7-BwI4lYRA9yTEVPRIqaN-v1miB74Ka5wcsiVCE1FOqkFLE20WA0uLkhLAuE9FDNspJfc3w

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately women-owned, pre-clinical accelerator based in Ann Arbor, Michigan focused on building companies that develop infectious disease therapeutics. A key aspect of our strategy is our Technology Accelerator, an ongoing collaborative process that lends our expertise and capabilities to entrepreneurs seeking to obtain the data and non-dilutive funding necessary to develop and/or commercialize their inventions. One focus is improving existing drug products by applying our versatile prodrug platform technologies to optimize therapy regimen for treating infectious diseases. Potential target indications include: influenza, HSV, VZV, CMV, EBV, poxvirus, HPV, Adenovirus, and RNA viruses. We currently employ ten full-time employees and a number of drug development consultants and generate annual revenues of approximately $2M from royalties and grants. Our team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation. Our research is conducted in a 7,200 sq. ft. facility of which 5,000 sq. ft. is wet lab space, with on-site analytical chemistry, formulation, cell culture equipment and in vivo testing capabilities.

iMetabolic Biopharma Corporation (iMBP) is an exciting early stage platform biopharma company that is developing First In Class therapeutics for the treatment of a number of diseases with high unmet medical need. Through the application of its proprietary iPlatform technology, iMBP has established itself as a Leader in TechBio, a nouveau field of drug discovery and development driven by technology innovation. Having already established a pipeline of five early stage therapeutic assets, with additional molecules already in design phase, iMBP is at the precipice in its next leg of evolution. Based in Tempe, AZ; iMBP is growing its operations to support the development of both its platform technology and therapeutic pipeline. iMBP is now strategically poised to become a disruptive force in the biopharma industry and is poised to move forward ground breaking science to help improve patient care. https://l.instagram.com/?u=https%3A%2F%2Flinktr.ee%2Fdr_urban_a_kiernan&e=AT1Hx7OAnm1Esgp1qPUsti_FJonAgqb7-BwI4lYRA9yTEVPRIqaN-v1miB74Ka5wcsiVCE1FOqkFLE20WA0uLkhLAuE9FDNspJfc3w

Therapeutic Systems Research Laboratories (TSRL), Inc. is a privately women-owned, pre-clinical accelerator based in Ann Arbor, Michigan focused on building companies that develop infectious disease therapeutics. A key aspect of our strategy is our Technology Accelerator, an ongoing collaborative process that lends our expertise and capabilities to entrepreneurs seeking to obtain the data and non-dilutive funding necessary to develop and/or commercialize their inventions. One focus is improving existing drug products by applying our versatile prodrug platform technologies to optimize therapy regimen for treating infectious diseases. Potential target indications include: influenza, HSV, VZV, CMV, EBV, poxvirus, HPV, Adenovirus, and RNA viruses. We currently employ ten full-time employees and a number of drug development consultants and generate annual revenues of approximately $2M from royalties and grants. Our team has broad experience in chemistry, molecular biology, biochemistry, analytical chemistry, in vivo animal model, PK/ADME, toxicology and formulation. Our research is conducted in a 7,200 sq. ft. facility of which 5,000 sq. ft. is wet lab space, with on-site analytical chemistry, formulation, cell culture equipment and in vivo testing capabilities.